Oral semaglutide for managing overweight and obesity [ID6188]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC